Back to search
Recurrent Burkitt Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Burkitt Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Burkitt Lymphoma trials you may qualify forThis study is a phase I study designed to evaluate the safety of CD19-CD22-CAR T cells. Primary Objective: To determine the safety profile and propose the rec…
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acu…
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblast…
To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozoga…
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion tha…
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelph…
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymph…